GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Skye Bioscience Inc.
Skye Bioscience is a biotechnology company developing cannabinoid-based drugs for the treatment of eye diseases. Its stock price is a speculative bet on the medical potential of these compounds and is dependent on the results of clinical trials.
Share prices of companies in the market segment - Narco farm
Skye Bioscience develops cannabinoid-based medications for the treatment of eye diseases such as glaucoma, leveraging their potential to reduce intraocular pressure. We classify it as a "Drug Farm" in terms of raw materials. The chart below shows the dynamics of this innovative segment.
Broad Market Index - GURU.Markets
Skye Bioscience is a pharmaceutical company developing cannabinoid-based drugs for the treatment of eye diseases, particularly glaucoma. Its unique approach makes it part of the GURU.Markets index. The chart below compares its performance with the market.
Change in the price of a company, segment, and market as a whole per day
SKYE - Daily change in the company's share price Skye Bioscience Inc.
Skye Bioscience, Inc.'s daily price fluctuations are a measure of the high volatility inherent in companies developing cannabinoid-based drugs. This metric reflects sensitivity to regulatory news and research data, and is key to assessing risk on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Narco farm
Skye Bioscience, Inc. is a biotechnology company focused on cannabinoids. This chart highlights the extreme volatility of the sector. Comparisons with SKYE's performance help assess it as a high-risk asset, dependent on clinical data and regulatory changes.
Daily change in the price of a broad market stock, index - GURU.Markets
Skye Bioscience develops cannabinoid-based medicines. The company operates at the intersection of biotechnology and the regulated cannabis industry, creating high volatility. Its shares respond to both scientific data and regulatory changes, adding unique dynamics to the market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Skye Bioscience Inc.
Skye Bioscience's year-over-year performance is a story of developing cannabinoid-based drugs for glaucoma. Its 12-month market cap is entirely dependent on clinical trial data. Success of its lead candidate could become the first approved drug in this class and fundamentally change the company's prospects in ophthalmology.
Annual dynamics of market capitalization of the market segment - Narco farm
Skye Bioscience, Inc. is a biopharmaceutical company developing cannabinoid-based drugs for the treatment of eye diseases. Its stock price is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in this innovative, yet controversial, field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Skye, which develops cannabinoid-based drugs, lives in a world of regulatory news rather than economic cycles. Its stock price is driven not by GDP, but by steps toward legalization and successes in clinical trials. Its chart is a story of high hopes and constant disappointments in the sector.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Skye Bioscience Inc.
Skye Bioscience develops cannabinoid-based drugs. Its monthly performance is closely tied to progress in clinical trials and changes in cannabis legislation. Positive research data or news of decriminalization could trigger a surge in interest in the stock.
Monthly dynamics of market capitalization of the market segment - Narco farm
Skye Bioscience develops cannabinoid-based drugs for the treatment of eye diseases such as glaucoma. They use a scientific approach to unlock the therapeutic potential of cannabis. The graph below shows the overall dynamics in the pharmaceutical sector, reflecting the growing interest in the legal and medical uses of cannabinoids.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
The pharmaceutical use of cannabinoids is an attempt to apply a scientific approach to drug development. The chart below illustrates the speculative nature of this biotech sector. Is Skye Bioscience moving with the times, or is its clinical data more important?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Skye Bioscience Inc.
Shares of Skye Bioscience, a company developing cannabinoid drugs for the treatment of eye diseases, reflect the risks and opportunities in this niche on a weekly basis. Share prices react to clinical trial data and changes in legislation regarding the medical use of cannabis.
Weekly dynamics of market capitalization of the market segment - Narco farm
Skye Bioscience develops cannabinoid-based treatments for eye diseases. The company combines biotech risks with the unique challenges of the cannabis sector. The chart below helps determine whether Skye's share price fluctuations are driven by its own clinical data or reflect broader trends and regulatory developments in the medical cannabis sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Skye Bioscience works with cannabinoids. This is a speculative and newsworthy market. The chart will show whether Skye shares exist in their own universe, reacting solely to regulatory and research news, or whether investors' risk appetite still ties them to the market.
Market capitalization of the company, segment and market as a whole
SKYE - Market capitalization of the company Skye Bioscience Inc.
Skye Bioscience's market capitalization tells the story of a biotech company developing cannabinoid-based drugs for the treatment of eye diseases, primarily glaucoma. Its volatile chart reflects an attempt to apply a scientific approach to what has long been a folk remedy. Its dynamics reflect the market's assessment of clinical trial data.
SKYE - Share of the company's market capitalization Skye Bioscience Inc. within the market segment - Narco farm
Skye Bioscience is a pharmaceutical company developing cannabinoid-based drugs for the treatment of eye diseases, particularly glaucoma. Its market cap reflects the potential of this new approach. The chart below shows how the market views its chances of creating a first-in-class ophthalmological drug.
Market capitalization of the market segment - Narco farm
Skye Bioscience is a biopharmaceutical company developing cannabinoid-based drugs for the treatment of eye diseases such as glaucoma. The chart below shows the market capitalization of this niche sector. Its dynamics reflect both the scientific interest and the regulatory challenges associated with the use of cannabinoids in medicine.
Market capitalization of all companies included in a broad market index - GURU.Markets
Skye Bioscience is a biopharmaceutical company developing cannabinoid-based drugs. Its market cap reflects the company's bet on the medical potential of these compounds being realized. Its performance on the overall chart reflects the evolving attitude toward cannabis, from a recreational substance to a potential basis for new medicines.
Book value capitalization of the company, segment and market as a whole
SKYE - Book value capitalization of the company Skye Bioscience Inc.
Skye Bioscience's balance sheet represents its capital earmarked for clinical trials of cannabinoid-based drugs for the treatment of eye diseases such as glaucoma. This provides a tangible, scientific foundation for exploring the therapeutic potential of these compounds. How has this unique biotech asset changed? The chart below shows its dynamics.
SKYE - Share of the company's book capitalization Skye Bioscience Inc. within the market segment - Narco farm
Skye Bioscience develops cannabinoid-based drugs for the treatment of eye diseases, which requires R&D laboratories. The chart shows the share of these science-intensive assets, reflecting the physical foundation of its research in this niche area.
Market segment balance sheet capitalization - Narco farm
Skye Bioscience develops cannabinoid-based drugs. This is a science-intensive process, where intellectual property is more important than production capacity in the early stages. A book value chart will show how "light" the company's capital base is.
Book value of all companies included in the broad market index - GURU.Markets
Skye Bioscience develops cannabinoid-based drugs. Its book value represents its research laboratories, clinical trial capital, and patent portfolio. The chart shows the material foundation upon which scientific research into the therapeutic potential of these molecules is built.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Skye Bioscience Inc.
Skye Bioscience's balance sheet is capital. But investors see potential in its cannabinoid-based drugs. The chart shows the "hope factor," which reflects the belief that its scientific research will lead to approved drugs.
Market to book capitalization ratio in a market segment - Narco farm
Skye Bioscience develops cannabinoid-based drugs for the treatment of eye diseases such as glaucoma. Its valuation is based on the potential of this unconventional therapeutic platform. The chart shows speculative investor interest in this emerging field of medicine.
Market to book capitalization ratio for the market as a whole
Skye Bioscience develops cannabinoid-based drugs for the treatment of eye diseases such as glaucoma. The company is exploring the therapeutic potential of cannabis in ophthalmology. This chart shows the overall valuation, but how does the market value a biotech company working in a controversial but potentially promising area of medical science?
Debts of the company, segment and market as a whole
SKYE - Company debts Skye Bioscience Inc.
Skye Bioscience develops cannabinoid-based drugs, a new and highly regulated field. This chart shows how the company is raising capital to conduct the clinical trials needed to prove the safety and efficacy of its drugs and obtain regulatory approval.
Market segment debts - Narco farm
Skye Bioscience is developing cannabinoid-based drugs for the treatment of eye diseases such as glaucoma. This is a niche and still-explored area of pharmaceuticals. This chart shows how the company is funding its clinical trials to prove the therapeutic potential of its molecules.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Skye Bioscience Inc.
Skye Bioscience develops cannabinoid-based drugs to treat various medical conditions. This chart shows how the company finances its research in a controversial but potentially breakthrough medical field. The debt burden here reflects not only the scientific but also the regulatory risks involved in developing a legal and approved drug.
Market segment debt to market segment book capitalization - Narco farm
Skye Bioscience develops cannabinoid-based drugs to treat eye diseases such as glaucoma. This chart shows the debt burden in the niche pharmaceutical sector. It helps understand how companies finance their unique clinical research in a field that still faces regulatory challenges.
Debt to book value of all companies in the market
Skye Bioscience develops cannabinoid-based drugs for the treatment of medical conditions. This is a highly specialized and risky area of pharmaceuticals, entirely dependent on research results and regulatory approvals. The market's total debt load chart doesn't reflect the company's key risks, which are scientific rather than financial.
P/E of the company, segment and market as a whole
P/E - Skye Bioscience Inc.
This chart for Skye Bioscience, a company developing cannabinoid-based drugs for eye diseases, shows the valuation of its niche research. The multiple reflects investors' confidence in the therapeutic potential of these compounds and the company's ability to successfully conduct clinical trials.
P/E of the market segment - Narco farm
Skye Bioscience's focus on developing cannabinoid drugs is a niche at the intersection of biotech and cannabis. This chart shows the average valuation for biopharmaceutical companies. It helps us understand that Skye is assessed based on both the scientific potential of its products and the regulatory risks associated with cannabis.
P/E of the market as a whole
Skye Bioscience, Inc. is a pharmaceutical company developing cannabinoid-based therapies for the treatment of eye diseases such as glaucoma. These are innovative applications of known molecules. This biotech sentiment chart helps understand how the market views the scientific validity and commercial potential of cannabinoid-based therapies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Skye Bioscience Inc.
Skye Bioscience is developing cannabinoid-based drugs for the treatment of eye diseases such as glaucoma. This chart illustrates speculative expectations related to the medical use of cannabinoids. The trend represents the market's assessment of the likelihood of success in its clinical programs.
%20P%2FE%20Skye%20Bioscience%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Skye-Bioscience-Inc.&v=1772632772086 "Chart of the company's future (projected) P/E Skye Bioscience Inc.")
Future (projected) P/E of the market segment - Narco farm
Skye Bioscience develops cannabinoid-based drugs for the treatment of eye diseases such as glaucoma. This chart shows average profitability expectations for the pharmaceutical sector. It provides an insight into how investors view the company's scientific approach to the use of cannabinoids in medicine and the potential of its developments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Narco-farm&v=1772632772101 "Future (projected) P/E graph of the market segment - Narco farm")
Future (projected) P/E of the market as a whole
Skye Bioscience, Inc. is a pharmaceutical company developing cannabinoid-based drugs for the treatment of eye diseases such as glaucoma. This chart shows investors' risk appetite. For a company operating at the intersection of biotechnology and the regulated cannabis industry, it reflects the market's willingness to fund innovative, yet controversial, treatment approaches.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772632772134 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Skye Bioscience Inc.
Skye Bioscience, Inc. is a pharmaceutical company developing cannabinoid-based drugs for the treatment of conditions such as glaucoma. The financial results shown in this chart are derived from clinical research expenses. It illustrates the company's efforts to scientifically substantiate and legalize the therapeutic use of cannabis derivatives.
Profit of companies in the market segment - Narco farm
Skye Bioscience develops cannabinoid-based medications for the treatment of medical conditions, primarily glaucoma. The company strives to harness the therapeutic potential of cannabis within a rigorous scientific and regulatory framework. This chart illustrates the emerging profitability of the medical marijuana sector, where clinical evidence and regulatory approval will pave the way to market.
Overall market profit
Skye Bioscience develops cannabinoid-based drugs for the treatment of eye diseases such as glaucoma. The company operates at the intersection of biotechnology and cannabis legalization. Its success depends on both scientific results and regulatory changes. It is an example of an innovative but high-risk niche within the large pharmaceutical industry.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Skye Bioscience Inc.
Skye Bioscience is a biopharmaceutical company developing cannabinoid-based drugs for the treatment of eye diseases such as glaucoma. The earnings forecast in this chart reflects analysts' expectations for clinical trial results in this innovative field.
%20profit%20of%20the%20company%20Skye%20Bioscience%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Skye-Bioscience-Inc.&v=1772632772313 "Graph of future (projected) profit of the company Skye Bioscience Inc.")
Future (predicted) profit of companies in the market segment - Narco farm
Skye Bioscience is developing cannabinoid-based drugs for the treatment of eye diseases, particularly glaucoma. This is an innovative application of cannabis derivatives in medicine. This chart shows the profit forecast for the narcotic pharmaceutical sector, allowing one to assess the market's perception of the prospects for the therapeutic use of cannabinoids.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Narco-farm&v=1772632772365 "Graph of future (predicted) profits of companies in a market segment - Narco farm")
Future (predicted) profit of the market as a whole
Skye Bioscience is a biopharmaceutical company developing cannabinoid-based drugs. This is a new and risky field. This chart, reflecting investor risk appetite, impacts the availability of capital for companies operating at the intersection of pharmaceuticals, biotech, and regulated substances.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772632772446 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Skye Bioscience Inc.
Skye Bioscience develops cannabinoid-based drugs for the treatment of eye diseases such as glaucoma. This chart shows how investors assess the company's potential at the intersection of biotech and medical marijuana. This valuation is a bet on clinical success and regulatory approval.
P/S market segment - Narco farm
Skye Bioscience develops cannabinoid-based drugs for the treatment of eye diseases such as glaucoma. This chart shows the average market capitalization to revenue ratio for the biotech industry. It reflects how the market views the company's scientific approach to using cannabinoids in traditional ophthalmology.
P/S of the market as a whole
Skye Bioscience is a biopharmaceutical company developing cannabinoid-based treatments for eye diseases, particularly glaucoma. These are innovative applications of known compounds. This overall market valuation chart helps understand investor sentiment toward companies working in the controversial but potentially promising field of medical cannabinoids.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Skye Bioscience Inc.
Skye Bioscience is developing cannabinoid-based drugs for the treatment of eye diseases such as glaucoma. This chart shows the company's valuation relative to its projected future sales. It reflects investor expectations for the success of its clinical trials and the potential of this new class of drugs.
%20P%2FS%20Skye%20Bioscience%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Skye-Bioscience-Inc.&v=1772632772756 "The graph of the company's future (projected) P/S Skye Bioscience Inc.")
Future (projected) P/S of the market segment - Narco farm
Skye Bioscience develops cannabinoid-based drugs for the treatment of diseases, primarily glaucoma. The company aims to exploit the therapeutic potential of cannabinoids in pharmaceuticals. This chart reflects investor expectations for its research program in this emerging and regulatory-challenging area of medicine.
%20P%2FS%20market%20segment%20graph%20-%20Narco%20farm&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Narco-farm&v=1772632772778 "Future (projected) P/S market segment graph - Narco farm")
Future (projected) P/S of the market as a whole
Skye Bioscience develops cannabinoid-based medications for the treatment of eye diseases. The company's success depends on the results of clinical trials and the regulatory environment. This general expectations chart for SKYE is not a direct driver. The company's value is determined by scientific data and progress in the legalization of medical cannabinoids.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772632772780 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Skye Bioscience Inc.
This chart illustrates the financial path of a biotech company. For Skye Bioscience, which focuses on developing cannabinoid-based drugs for eye diseases, it reflects the funding needed to conduct clinical trials.
Sales of companies in the market segment - Narco farm
Skye Bioscience, Inc. develops cannabinoid-based drugs for the treatment of eye diseases such as glaucoma. The company takes a pharmaceutical approach to medical cannabis. This chart shows the pharmaceutical sector's revenue. Skye's success could legitimize cannabinoids as a class of medicine and open a new market.
Overall market sales
Skye Bioscience develops cannabinoid-based drugs for the treatment of eye diseases such as glaucoma. The company operates at the intersection of pharmaceuticals and the legalization of cannabis for medical purposes. Its success depends on clinical data and regulatory decisions, and it is part of a new, rapidly growing segment of biotechnology.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Skye Bioscience Inc.
Skye Bioscience is developing cannabinoid-based medications for the treatment of ocular diseases such as glaucoma. Future sales projections depend on the success of clinical trials and regulatory approval of its products.
%20sales%20of%20the%20company%20Skye%20Bioscience%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Skye-Bioscience-Inc.&v=1772632772950 "Schedule of future (projected) sales of the company Skye Bioscience Inc.")
Future (projected) sales of companies in the market segment - Narco farm
Skye Bioscience, Inc. is developing cannabinoid-based drugs for the treatment of eye diseases. The forecast for the cannabis-based pharmaceutical sector shows gradual scientific and regulatory acceptance. The graph reflects the significant potential for therapeutic use of these substances in serious medicine.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Narco-farm&v=1772632773024 "Schedule of future (projected) sales of companies in the market segment - Narco farm")
Future (projected) sales of the market as a whole
Skye Bioscience is developing cannabinoid-based drugs for the treatment of eye diseases. The company's success depends on clinical trials and regulatory approval. This overall economic activity schedule does not impact medical need, but it may impact the availability of capital for research in this highly specialized and innovative field of pharmaceuticals.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772632773060 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Skye Bioscience Inc.
Skye Bioscience is a biopharmaceutical company developing cannabinoid-based treatments for eye diseases such as glaucoma. Being in the clinical trials stage, it incurs significant R&D expenses. This chart shows the company's investment in exploring the therapeutic potential of cannabinoids.
Market segment marginality - Narco farm
Skye Bioscience develops cannabinoid-based drugs for the treatment of eye diseases, particularly glaucoma. Profitability depends on the success of clinical trials and regulatory approval. This chart reflects the company's operational structure in the innovative and legally complex pharmaceutical industry compared to its competitors.
Market marginality as a whole
Skye Bioscience, Inc. is a biopharmaceutical company developing cannabinoid-based drugs for the treatment of eye diseases such as glaucoma. This chart shows the company's overall profit margin. Compared to this, Skye is a high-risk bet on the medical use of cannabis derivatives. Its future depends on the results of clinical trials and the regulatory environment.
Employees in the company, segment and market as a whole
Number of employees in the company Skye Bioscience Inc.
Skye Bioscience is a biopharmaceutical company developing cannabinoid-based drugs for the treatment of eye diseases. Its small team is focused on clinical trials. Growth on this chart would indicate the advancement of its lead candidate into later-stage trials, which requires the involvement of more specialists.
Share of the company's employees Skye Bioscience Inc. within the market segment - Narco farm
Skye Bioscience develops cannabinoid-based drugs for the treatment of diseases, primarily glaucoma. This chart illustrates its unique scientific niche. It reflects the percentage of chemists and pharmacologists specializing in the therapeutic potential of cannabinoids in ophthalmology that Skye Bioscience attracts for its research.
Number of employees in the market segment - Narco farm
Skye Bioscience is developing cannabinoid-based drugs for the treatment of eye diseases such as glaucoma. This graph illustrates the medical uses of cannabis. The growing number of scientists in this field demonstrates scientific interest in studying the endocannabinoid system to develop new, legal, and effective medications.
Number of employees in the market as a whole
Skye Bioscience, Inc. develops cannabinoid-based drugs for the treatment of eye diseases. This sector combines the risks of biotech with the regulatory uncertainty of cannabis. The overall economic situation, reflected in this chart, has little impact on Skye. Their future depends on the results of clinical trials and regulatory changes.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Skye Bioscience Inc. (SKYE)
Skye Bioscience develops cannabinoid-based drugs to treat eye diseases such as glaucoma. This chart shows how the market values niche biotechs. Their high market cap per employee reflects the potential of their unique treatment approach and the value of their intellectual property, not the company's size or current sales.
%20of%20the%20company%20Skye%20Bioscience%20Inc.%20(SKYE)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Skye-Bioscience-Inc.-SKYE&v=1772632773255 "Chart of market capitalization per employee (in thousands of dollars) of the company Skye Bioscience Inc. (SKYE)")
Market capitalization per employee (in thousands of dollars) in the market segment - Narco farm
Skye Bioscience develops cannabinoid-based drugs, a niche market within the pharmaceutical industry. This chart shows how investors view the company's scientific developments and its potential in this emerging market. The high cost per employee reflects the belief that a small team can create a sought-after and patented product.
%20by%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Narco-farm&v=1772632773274 "Market capitalization per employee (in thousands of dollars) by market segment - Narco farm")
Market capitalization per employee (in thousands of dollars) for the overall market
Skye Bioscience develops cannabinoid-based drugs for the treatment of conditions such as glaucoma. This chart reflects the high employee valuation, as the company operates in an innovative, albeit regulatory-challenging, area of pharmaceuticals where scientific breakthroughs can create a new market.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772632773370 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Skye Bioscience Inc. (SKYE)
Skye Bioscience is a biotech company developing cannabinoid-based drugs for the treatment of diseases, particularly glaucoma. They are trying to create "medical marijuana" in the form of targeted therapy. This is R&D. This metric is negative. It reflects how much the company spends on each scientist to conduct clinical trials and prove the effectiveness of its drugs.
%20Chart%20Skye%20Bioscience%20Inc.%20(SKYE)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Skye-Bioscience-Inc.-SKYE&v=1772632773394 "Company Profit Per Employee (in thousands of dollars) Chart Skye Bioscience Inc. (SKYE)")
Profit per employee (in thousands of dollars) in the market segment - Narco farm
Skye Bioscience (SKYE) is a biotech company developing cannabinoid-based drugs for the treatment of conditions such as glaucoma. For a clinical-stage company, this graph is a theoretical benchmark. All of SKYE's current operations are unprofitable and focused on research. Success would mean their team has created a drug that will generate profits above industry standards.
%20in%20the%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Narco-farm&v=1772632773406 "Chart of profit per employee (in thousands of dollars) in the market segment - Narco farm")
Profit per employee (in thousands of dollars) for the market as a whole
Skye Bioscience (SKYE) develops cannabinoid-based drugs for the treatment of conditions such as glaucoma. It is a biotech company operating in a complex regulatory environment. Being in the R&D stage, its profit per employee is negative, reflecting the cost of the scientific team advancing these specific drugs through clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772632773426 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Skye Bioscience Inc. (SKYE)
Skye Bioscience is developing cannabinoid-based treatments for ophthalmic diseases. This graph reflects its status as a clinical-stage R&D company. Lack of revenue is normal. In the future, this metric will become a measure of the commercial success of its innovative therapeutic approaches.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Skye-Bioscience-Inc.-SKYE&v=1772632773446 "Sales chart per company employee Skye Bioscience Inc. (SKYE)")
Sales per employee in the market segment - Narco farm
Skye Bioscience is a biotech company developing cannabinoid-based drugs for the treatment of eye diseases (e.g., glaucoma). At the R&D stage, this metric reflects how effectively their research team generates revenue (e.g., from partnerships) per employee in this specific pharmaceutical niche.
Sales per employee for the market as a whole
Skye Bioscience is a biotech company developing cannabinoid-based drugs for the treatment of conditions such as glaucoma. It's an R&D company. This chart shows revenue per employee. For a clinical-stage company, this metric is expected to be zero or very low (from grants), as the entire research staff is focused on drug development.
Short shares by company, segment and market as a whole
Shares shorted by company Skye Bioscience Inc. (SKYE)
Skye Bioscience develops cannabinoid-based drugs for the treatment of diseases, particularly glaucoma. This chart shows bearish bets. Bears may be skeptical of the therapeutic potential of cannabinoids or expect that clinical trials will not demonstrate the company's drugs' superiority over existing glaucoma treatments.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Skye-Bioscience-Inc.-SKYE&v=1772632773637 "Short Shares Chart for the Company Skye Bioscience Inc. (SKYE)")
Shares shorted by market segment - Narco farm
Skye Bioscience develops cannabinoid-based drugs for the treatment of diseases, particularly glaucoma. This sector faces high regulatory risk. This chart shows the overall short positions in the "pharma-cannabis" sector. The high short position here reflects deep investor skepticism regarding the timeline for the legalization and commercialization of these treatments.
Shares shorted by the overall market
Skye Bioscience (SKYE) operates in the speculative cannabinoid biotech sector. When this general fear indicator rises, investors flee risk. They sell off the "double risk": both unprofitable biotechs and the cannabis sector, which has its own regulatory challenges.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Skye Bioscience Inc. (SKYE)
Skye Bioscience operates in the speculative biotech sector related to cannabinoids (glaucoma treatment). This chart can soar above 70 on positive R&D news. Oversold territory (<30) often reflects setbacks, delays, or general investor risk aversion in both biotech and cannabis.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Skye-Bioscience-Inc.-SKYE&v=1772632773867 "RSI 14 indicator chart for the company's stock Skye Bioscience Inc. (SKYE)")
RSI 14 Market Segment - Narco farm
Skye (SKYE) is "cannabis" 2.0. They're *not* "farmers," but a *biotech* that develops *medicines* (for the eyes) based on *cannabinoids*. The "Narco farm" (cannabis) sector is the "king" of "hype." RSI_14_Seg shows the "temperature" of the *entire* industry. It helps us understand: is SKYE's growth due to their R&D or the *general* "hype"?
RSI 14 for the overall market
Skye Bioscience, a cannabinoid biotech, sees a dual appetite for risk in this chart. In times of euphoria, investors are willing to fund both speculative biotech and the hyped cannabis sector. In times of panic, capital flees both these unprofitable sectors, creating a funding crisis for Skye.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SKYE (Skye Bioscience Inc.)
Skye Bioscience is a biotech company developing cannabinoid-based drugs for the treatment of eye diseases, particularly glaucoma. This chart shows the average 12-month forecast of analysts, representing their collective speculative bet on the success of clinical trials in this niche.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SKYE-Skye-Bioscience-Inc.&v=1772632773940 "A chart showing analyst consensus forecasts for the expected stock price. SKYE (Skye Bioscience Inc.)")
The difference between the consensus estimate and the actual stock price SKYE (Skye Bioscience Inc.)
Skye Bioscience (SKYE) is a biotech company developing cannabinoid-based drugs for the treatment of eye diseases (glaucoma). This R&D bet is on "medical marijuana." This chart shows their R&D valuation. It measures the gap between the price and the consensus target, reflecting whether analysts believe they can prove efficacy.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SKYE-Skye-Bioscience-Inc.&v=1772632773957 "A chart showing the difference between the consensus forecast and the actual stock price. SKYE (Skye Bioscience Inc.)")
Analyst consensus forecast for stock prices by market segment - Narco farm
Skye Bioscience is a biotech company developing cannabinoids (compounds from cannabis) into medicine, specifically eye drops for glaucoma. This chart shows analysts' overall expectations for the "pharma cannabis" sector. It reflects whether experts believe in the medicinal potential of this plant.
Analysts' consensus forecast for the overall market share price
Skye Bioscience is a biotech company developing cannabinoid-based drugs for the treatment of eye diseases, particularly glaucoma. This chart shows the overall risk appetite. For Skye, which operates at the intersection of biotech and cannabis, overall market optimism is important, but their success also depends on regulatory barriers for marijuana-based drugs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Skye Bioscience Inc.
Skye Bioscience is a biotech company trying to tame cannabis. They are developing patented, synthetic cannabinoid derivatives (THC, CBD) to treat medical conditions, primarily glaucoma (eye drops). This chart summarizes their R&D progress, reflecting their progress in clinical trials and their potential to develop weed into an FDA-approved drug.
AKIMA Market Segment Index - Narco farm
Skye Bioscience develops cannabinoid-based (synthetic) medications for the treatment of medical conditions, primarily glaucoma (eye drops). This chart shows the average pharmaceutical sector index. It helps investors assess how Skye's niche approach to using cannabinoids in medicine compares to the industry average.
The AKIM Index for the overall market
Skye Bioscience is a biotech company developing drugs that target the endocannabinoid system for the treatment of glaucoma and obesity. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative scientific story fits in with overall economic trends and interest in new mechanisms of action.
